The assessment discusses fifty eight peptides in numerous clinical phases, indicating a sturdy pipeline of peptide therapies focusing on PPIs. Co-formulation with other permeation enhancers, enzyme inhibitors, and hydrogels have also been used to enable the oral administration of other peptide medicine, for example octreotide and insulin, which